The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Evaluation of a nonbiologic nanoparticle form of paclitaxel in metastatic pancreatic cancer.
Kouros Motamed
Employment or Leadership Position - Igdrasol
Stock Ownership - Igdrasol
Larn Hwang
Employment or Leadership Position - Igdrasol
Stock Ownership - Igdrasol
Chao Hsiao
Employment or Leadership Position - Igdrasol
Stock Ownership - Igdrasol
Vuong N. Trieu
Employment or Leadership Position - Igdrasol
Stock Ownership - Igdrasol